Loading
Avicanna Inc. Stock: price and insider trades · Canada
Avicanna Inc.: what insiders have been doing
Avicanna Inc. belongs to the Health Care sector. Filings by its managers are published through SEDI. Over the twelve months to 18 October 2026, the company's managers filed 26 filings, from 4 insiders.
Purchases and sales both appear in the filings: 7 purchases (2 insiders, €89k) and 1 sale (1 insider, €5,217). Netting one side against the other leaves €84k of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. At €18k, the purchase published on 18 June 2026 by Michael Kott is the largest of the period (0.18% of market cap). Among those who bought: 2 senior executives.
The most recent open-market purchase was published on 13 September 2026, 34 days ago. Typically, a trade is published a median of 4 days after it takes place. Until a filing is published, the market cannot know about the trade.
With 26 filings in twelve months, the company is more active than the median of 12 filings across the 2,120 companies we follow on the same exchange. Since 2026, the database holds 7 purchases and 1 sale by insiders of the company.
In the same sector, recent insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. also feature in our signals. Every figure here comes from the filings published by SEDI and describes the past, not future prices; it is not investment advice.
Insider Decl.
26
Thresholds
n/a
Buy Volume
€88,975
7 ops. · all time
Sell Volume
€5,217
1 ops. · all time
Who traded when
BuySaleMichael Kott5 buys
Ozgur Kilic2 buys
Nicholas Hilborn1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,671 of 24,148 companies
22.5
score / 100
Value13
Quality32
FCF yld-11%
Earn yld-21%
EV/EBITDA·
ROE-30%
Gross mgn53%
Net mgn-11%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CA$0.12
Analyst consensus
Income statement
RevenueCA$25.5M
Gross profitCA$13.5M53% margin
EBITDA-CA$2M-8% margin
Net income-CA$2.8M-14.8% margin
Valuation
P/Book3.4x
Beta0.35
Balance sheet & cash
Market capCA$15.5M
Free Cash Flow-CA$1.4M
Debt / Equity1%
Profitability & ownership
ROE-30.0%
ROA-9.9%
% insiders21.3%
% institutions0.0%
Last declaration on 13 September 2026
Declarations26 total
233,000 shares@ CA$0.1050.17% mcap23.7% of flowCommon SharesTSXSEDI:4777025
Canonical exit: 9 Dec 2026 (T+90)
1,000,000 sharesOptionsTSXSEDI:4739647
75,000 sharesOptionsTSXSEDI:4739645
628,418 shares@ CA$0.130.56% mcap49.8% of flowCommon SharesTSXSEDI:4739639
403,418 shares@ CA$0.130.36% mcap32.2% of flowRights Restricted Share UnitsTSXSEDI:4739638
225,000 shares@ CA$0.130.20% mcap18.0% of flowRights Restricted Share UnitsTSXSEDI:4739637
90,909 shares@ CA$0.130.080% mcap7.4% of flowCommon SharesTSXSEDI:4739448
150,000 shares@ CA$0.250.24% mcap43.9% of flowOptionsTSXSEDI:4738783
25,000 shares@ CA$0.140.023% mcap4.1% of flowOptionsTSXSEDI:4738780
OptionsTSXSEDI:4738778
65,079 shares@ CA$0.130.054% mcap9.8% of flowCommon SharesTSXSEDI:4738777
151,473 sharesRights Restricted Share UnitsTSXSEDI:4738772
226,473 shares@ CA$0.110.16% mcap29.1% of flowRights Restricted Share UnitsTSXSEDI:4738769
Rights Restricted Share UnitsTSXSEDI:4738762
86,394 shares@ CA$0.130.072% mcap13.0% of flowCommon SharesTSXSEDI:4738738
225,500 shares@ CA$0.130.18% mcap18.4% of flowCommon SharesTSXSEDI:4737265
Canonical exit: 16 Sept 2026 (T+90)
54,500 shares@ CA$0.130.047% mcap4.4% of flowCommon SharesTSXSEDI:4736800
Canonical exit: 15 Sept 2026 (T+90)
109,000 shares@ CA$0.13040.095% mcap8.9% of flowCommon SharesTSXSEDI:4736426
Canonical exit: 14 Sept 2026 (T+90)
115,000 shares@ CA$0.200.15% mcap22.1% of flowWarrantsTSXSEDI:4735889
WarrantsTSXSEDI:4735888
230,000 shares@ CA$0.150.23% mcap33.1% of flowCommon SharesTSXSEDI:4735887
211,000 shares@ CA$0.13290.21% mcap17.6% of flowCommon SharesTSXSEDI:4735765
Canonical exit: 13 Sept 2026 (T+90)
166,500 sharesWarrantsTSXSEDI:4735146
333,000 shares@ CA$0.150.38% mcap31.4% of flowCommon SharesTSXSEDI:4735142
160,000 shares@ CA$0.136621.1% of flowCommon SharesTSXSEDI:4724461
Canonical exit: 25 Aug 2026 (T+90)
25 of 26 declarations
About Avicanna Inc.
Avicanna Inc. is a Canadian company focused on the development of pharmaceutical products derived from cannabis. It specializes in research, formulation, and commercialization of innovative therapeutic solutions.
